Anika Therapeutics appoints Griffin as CEO, Blanchard as Executive Chair

Anika Therapeutics (ANIK) announced that Stephen Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Griffin will succeed Cheryl Blanchard, Ph.D., who will become Executive Chair of the Board of Directors. In addition, John Henneman, III, Director since 2020, has been appointed Lead Independent Director.